Amonafide

Amonafide
Systematic (IUPAC) name

5-amino-2-[2-(dimethylamino)ethyl]-1H-benzo[de]isoquinoline-1,3(2H)-dione
Clinical data
Identifiers
CAS Registry Number	69408-81-7
ATC code	None
PubChem	CID 50515
ChemSpider	45804^Y
UNII	1Q8D39N37L^Y
KEGG	D10090^Y
ChEMBL	CHEMBL428676^Y
Chemical data
Formula	C₁₆H₁₇N₃O₃
Molecular mass	283.325 g/mol
SMILES O=C2c1c3c(ccc1)cc(cc3C(=O)N2CCN(C)C)N
InChI InChI=1S/C16H17N3O2/c1-18(2)6-7-19-15(20)12-5-3-4-10-8-11(17)9-13(14(10)12)16(19)21/h3-5,8-9H,6-7,17H2,1-2H3 ^Y Key:UPALIKSFLSVKIS-UHFFFAOYSA-N ^Y
Y (what is this?) (verify)

Amonafide (originally AS1413) (INN, trade name Quinamed) is a drug that is being studied in the treatment of cancer. It belongs to the families of drugs called topoisomerase inhibitors and DNA intercalators.

It is being developed as an anti-cancer therapy by Antisoma.^[1]

As of 2008, it is in Phase III clinical trials. e.g. In March 2010 it is Phase III trial against secondary acute myeloid leukaemia (AML).^[2]

References

↑ http://www.genengnews.com/news/bnitem.aspx?name=78979622
↑ http://clinicaltrials.gov/ct2/show/NCT00715637 "Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study"

External links

Amonafide entry in the public domain NCI Dictionary of Cancer Terms
Clinical trials of amonafide at ClinicalTrials.gov

This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".